Abstract: Metabotropic glutamate receptor 7 (mGluR7) is localized presynaptically at the active zone of neurotransmitter release. Unlike mGluR4 and mGluR8, which share mGluR7's presynaptic location, mGluR7 shows low affinity for glutamate and is activated only by high glutamate concentrations. Its wide distribution in the central nervous system (CNS) and evolutionary conservation across species suggest that mGluR7 plays a primary role in controlling excitatory synapse function. High mGluR7 expression has been observed in several brain regions that are critical for CNS functioning and are involved in neurological and psychiatric disorder development. Until the recent discovery of selective ligands for mGluR7, techniques to elucidate its role in neural function were limited to the use of knockout mice and gene silencing. Studies using these two techniques have revealed that mGluR7 modulates emotionality, stress and fear responses. N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082) was reported as the first selective mGluR7 allosteric agonist. Pharmacological effects of AMN082 have not completely confirmed the mGluR7-knockout mouse phenotype; this has been attributed to rapid receptor internalization after drug treatment and to the drug's apparent lack of in vivo selectivity. Therefore, the more recently developed mGluR7 negative allosteric modulators (NAMs) are crucial for understanding mGluR7 function and for exploiting its potential as a target for therapeutic interventions. This review presents the main findings regarding mGluR7's effect on modulation of synaptic function and its role in normal CNS function and in models of neurologic and psychiatric disorders.
INTRODUCTION
The actions of glutamate, the main excitatory neurotransmitter in the mammalian central nervous system (CNS), can be finely modulated by metabotropic glutamate receptors (mGluRs) [1, 2] . mGluRs are G-protein coupled receptors and are divided into three groups based on sequence homology, pharmacological profile, and signal transduction mechanisms [3] . Eight mGluRs (mGluR1-8) have been identified and classified into three groups: group I, consisting of mGluR1 and mGluR5, group II, consisting of mGluR2 and mGluR3, and group III, consisting of mGluR4, mGluR6, mGluR7, and mGluR8. Group I receptors are coupled to phospholipase C (PLC) activation, while Group II and III are associated with adenylate cyclase inhibition [3, 4] . mGluRs modulate glutamatergic transmission at several levels depending on their expression at nerve terminals, postsynaptic sites, or glia [5, 6] (Fig. 1) . Group I mGluRs are mainly located at the postsynaptic regions, where they increase neural excitability, whereas group II and group III are primarily located at presynaptic terminals and [11, [13] [14] [15] . mGluR7 receptors are mainly located within the presynaptic active zone [11, 14, 16] where they serve as autoor hetero-receptors, inhibiting glutamate or GABA release, respectively [16, 17] (Fig. 1) . mGluR7 receptor activation also leads to increased signaling pathways potentiating neurotransmitter release in cerebrocortical nerve terminal preparations from adult rats [18] . However, direct facilitation of neurotransmitter release by mGluR7 has not yet been demonstrated on neurons in vitro or in vivo. In the globus pallidus and striatum, mGluR7 is expressed at postsynaptic sites and not just at presynaptic ones [19] . Postsynaptic mGluR7 receptors have also been observed on amacrine cells at retinal synapses [20] , on olfactory bulb glomeruli [21] , and on prefrontal cortex pyramidal neurons [22] . So far, five splice variants of the mGluR7 receptor have been characterized, called mGluR7a-e. These splice variants exhibit different, but often overlapping, expression patterns [12, [23] [24] [25] . mGluR7a is generally more widely expressed than mGluR7b [14, 24] . mGluR7c and mGluR7d are found in non-neuronal tissues within the CNS [25] . In addition to its CNS localization, mGluR7 is also expressed in peripheral tissues, such as the colon [26] , stomach [27] , and adrenal glands [28] , and in hair cells and spiral ganglion cells of the inner ear [29] .
ROLE OF mGluR7 IN SYNAPTIC TRANSMISSION
mGluR7 has low affinity for glutamate; it is recruited only under high neurotransmitter concentrations and thus acts as an auto-receptor to inhibit further glutamate release [30] . L-2-amino-4-phosphonobutyrate (L-AP4) can bind to mGluR7 at high concentrations and inhibits glutamate release via N-type Ca 2+ channel inhibition [31] (Fig. 1) . Recently, studies using the selective mGluR7 positive allosteric agonist N,N'-bis(diphenylmethyl)-1,2-ethanediamine dihydrochloride (AMN082) and the mGluR7 negative allosteric modulator 7-hydroxy-3-(4-iodophenoxy)-4H-chromen-4-one (XAP044) have demonstrated that mGluR7 modulates excitatory/inhibitory transmission in the hippocampus [32] [33] [34] [35] , thalamus [36, 37] , nucleus accumbens [38, 39] , PAG [40] and amygdala [41] [42] [43] . Effects of AMN082 Fig. (1) . Synaptic distribution of mGluRs with group I localized mainly postsynaptically and group II and III localized presynaptically. The mGluR7 receptor is found on both glutamatergic and GABAergic terminals, functioning as an auto-and hetero-receptor and controlling neurotransmitter release. Together with excitatory amino acid transporters (EAAT), presynaptic mGluR7 receptors reduce glutamate levels under conditions of high glutamate concentration. mGluR7 binding and signaling proteins are also reported. VGAT, vesicular GABA transporter; vGluT, vesicular glutamate transporter; EAAT, excitatory amino acid transporter; NMDA, N-methyl-D-aspartate receptor; AMPA, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor, KA, kainic acid receptor, CaM, Ca 2+ -calmodulin complex, PKC, protein kinase C, AC, adenylate cyclase, PICK1, PDZ domain-containing protein, Ca 2+ , N type Ca 2+ channels, GIRKs, G-protein-coupled inwardly rectifying potassium channels.
differ depending on the brain region. Specifically, AMN082 decreases GABA and increases glutamate levels in the nucleus accumbens [39] and amygdala [42] . Conversely, it decreases glutamate release in the PAG [40] . In some instances, mGluR7 facilitates glutamatergic release, likely via interactions with the exocytose machinery [18] . Apart from Gi/o-protein coupling and the consequent inhibition of adenylyl cyclase and cAMP formation [1], mGluR7 also inhibits N-and P/Q-type Ca 2+ channels in the transfected cerebellar granule cells [44] , brainstem [45] , and hippocampus [46, 47] . Finally, mGluR7 also modulate synaptic function through G-protein-coupled inwardly rectifying potassium channels (GIRKs) [48] . mGluR7 activity is finely modulated: calmodulin binds to the carboxyl terminus of mGluR7 in a Ca 2+ -dependent manner (CaM). The CaM-binding domain, located at the end of the seventh trans-membrane segment, can be competitively phosphorylated by protein kinase C (PKC), which inhibits binding of the Ca 2+ /CaM complex to the receptor [49] . PKC inhibits mGluR7's effect on neurotransmitter release by preventing coupling of mGluR7 receptors to their requisite G proteins [50] . PKC-mediated phosphorylation is also a key mechanism regulating constitutive and activity-dependent mGluR7 expression. Two events, mGluR7 phosphorylation by PKC and mGluR7 binding to the PDZ domain-containing protein PICK1, lead to increased mGluR7 expression [51] . mGluR7 expression is also increased by inhibitors of protein phosphatase 1 (PP1), which counteracts the action of PKC on mGluR7 [52] . Rodent studies suggest that the interaction of mGluR7 and PICK1 is critical to proper neural function, as disruption of the mGluR7a-PICK1 complex is sufficient to induce absence epilepsy-like seizures [53] . It has also been suggested that mGluR7 activity is protective against several neurological disorders. mGluR7 modulates GABAergic interneuron synapse development through its interaction with Elfn1 protein, whose abnormal expression during development is associated with epilepsy and attention deficit hyperactivity disorders [54] . mGluR7 also prevents NMDA-induced excitotoxicity of basal forebrain (BF) cholinergic neurons; degeneration of these neurons represents an early pathological event in Alzheimer's disease. This protection mechanism through mGluR7 activation is selectively inhibited by β-amyloid (Aβ). Aβ increases p21-activated kinase activity and decreases cofilin-mediated actin depolymerization through a p75(NTR)-dependent mechanism [55] .
EXAMINATION OF THE mGluR7 KNOCK-OUT PHENOTYPE
Due to the lack of available ligands with specificity for mGluR7, mGluR7-knockout mice were traditionally the only tool available to examine the physiological role of mGluR7 and its involvement in cognitive, affective, and sensory behaviors [56] . Mice lacking mGluR7 receptors showed reduced short-term neural plasticity in the hippocampus [57] suggesting a role for mGluR7 in the molecular mechanisms underlying cognition. In line with this evidence, mGluR7-knockout mice displayed some impairments in learning and memory [58] [59] [60] . Specifically, these mice showed normal behavior in the T-maze [58] but impairments in both the 4-arm and 8-arm maze tasks, which require intact working memory capacity. Intriguingly, after training, mGluR7-knockout mice showed test performance similar to the their wild type counterparts, implying that training can overcome baseline differences in working memory capacity [58, 59, 61] . Similarly, mGluR7-deficient mice exhibited impairments in the Morris water maze, although they achieved similar performance to wild type mice after training [62] . It has been thus proposed that mGluR7 is involved in the molecular mechanisms underlying short-term working and spatial memory whereas long-term memory operates in an mGluR7-independent manner [58, 62] . Recent studies have also demonstrated that mGluR7 is involved in conditioned fear responses. Mice lacking mGluR7 displayed delayed extinction of a conditioned fear response in the conditioned emotional responses (CER) procedure, but the initial acquisition of fear responses appeared unaltered in these mice [62, 63] . This may be due to the different neural substrates involved in acquisition (the amygdala) and extinction (the hippocampus and prefrontal cortex) of CER. However, mGluR7-deficient mice displayed reduced shock-induced freezing and impaired conditioned taste aversion, which are both amygdaladependent paradigms [64] [65] [66] . The reason for these discrepant findings may be the different experimental strategies used in the two studies. The CER study used shocks that were signaled by auditory cues [62] , and the conditioned taste aversion study used saccharin avoidance after pairing it with intraperitoneal injection of LiCl, an agent which causes transient visceral malaise [66] . mGluR7-knockout mice exhibited reduced anxiety-like responses in several behavioral tests such as the elevated plus maze, staircase, marble burying, light-dark box, open field, and stress-induced hyperthermia tests [62, 67] . The behavioral profile of these mice suggests a role for mGluR7 in emotional disorders [68] . In addition, and in accordance with their anxiolytic-like phenotype, mGluR7 knockout mice also displayed reduced stress responses and activity of the hypothalamic-pituitaryadrenal (HPA) axis [70] . mGluR7-deficient mice showed increased expression of hippocampal glucocorticoid and 5-hydroxytriptamine 1A receptors (GR and 5-HT 1A ) [70] . Increased GR and 5-HT 1A expression in response to the lack of mGluR7 suggests enhanced negative feedback of the HPA axis, which is hyperactive in depressant and anxietylike phenotypes [71, 72] . Accordingly, mGluR7-knockout mice showed increased HPA suppression in response to dexamethasone and increased levels of brain derived neurotrophic factor (BDNF), both positive indexes of antidepressant activity [73, 74] . Consistently, mGluR7-knockout mice exhibited antidepressant-like profiles in the tail suspension and forced swim tests [67, 75] . Mice lacking the mGluR7 receptor displayed an increased seizure vulnerability and reduced anticonvulsant effects of (RS) phosphonophenylglycine (PPG), a broad spectrum group III mGluR agonist [56] , indicating a potential neuroprotective role for mGluR7 [76] . The phenotype of the mGluR7 knockout mouse is summarized in Table 1 . Altogether, mGluR7-knockout mouse strategies have largely contributed to uncovering the role of mGluR7 in epilepsy, cognition, and emotion regulation. One critical limitation of conventional knockout strategies, however, is that the constitutive lack of a gene may lead to compensatory effects from related proteins, especially during development, and this may confound some outcome measures. To address this concern, the development of selective mGluR7 ligands for direct activation/blockade of the receptor in the adult organism is critical.
PHARMACOLOGICAL MANIPULATION OF mGluR7
mGluR7 displays low affinity for the "classic" group III orthosteric agonists such as L-AP4 and L-SOP [77] . Moreover, orthosteric receptor activation requires an α-amino acid moiety and distal phosphonic group, which makes these compounds too hydrophilic to penetrate the blood-brain-barrier for subsequent brain exposure [78] . ACPT-1 can penetrate the blood-brain-barrier, but has shown the same low selectivity for mGluR7 [79, 80] . The competitive group III mGluR antagonist, LY341495, shows the highest potency but is scarcely selective, since it is also a potent antagonist at group II mGluRs [81] . MSOP, CPPG, and MAP4 are more selective for group III mGluRs but display weak potency [30, 77] . Targeting allosteric binding sites has permitted drug developers to overcome the scarce selectivity and hydrophilicity associated with orthosteric compounds. Allosteric binding sites are less conserved among the other mGluR family members and do not require hydrophilic moieties [82] . AMN082 was developed as the first selective positive allosteric modulator (PAM) for mGluR7 [78] . The interest in AMN082 has waned because of its scarce selectivity in vivo [83] . AMN082 fully activates mGluR7 [78, 84] , and its action is not blocked by mGluR7 orthosteric antagonists [78] . AMN082, however, is rapidly metabolized into an active compound in vivo, which inhibits monoamine transporter activity. Consistent with the mGluR7-knockout mouse phenotype, AMN082 increases plasma corticosterone and adrenocorticotropic hormone (ACTH) levels [78] . AMN082 has been shown to reduce fear acquisition and LTP in the amygdala, but improve fear extinction [85, 86] . AMN082's effect on fear extinction is in line with the resistance to fear extinction observed in mGluR7-deficient mice, whereas its effect on fear acquisition is divergent from the phenotype of mGluR7-deficient mice, which displayed no abnormality in fear acquisition [62] . AMN082's effects on emotional behavior also conflict those of mGluR7-knockout phenotype. AMN082 paradoxically produced anxiogenic-and anxiolyticlike effects [68, 69, 85, [88] [89] [90] and also demonstrated antidepressant-like activity [89, 91, 92] , the latter being in contrast to the mGluR7-knockout phenotype. AMN082 also facilitated nociception when microinjected into the ventrolateral PAG (VL PAG), central nucleus of the amygdala (CeA), or nucleus tractus solitarius (NTS) [40, 88, 93] . AMN082 changed the activity of neurons that respond to pain stimuli in the rostral ventromedial medulla (RVM) and decreased glutamate release into the VL PAG [40] , consistently with descending pathway inhibition and pain facilitation [40, [94] [95] [96] . AMN082 has been shown to facilitate nociception in some studies [97] ; however, it reduced pain responses in other studies [98, 99] . One possible explanation for the contradictory effects of AMN082 is the rapid and long-lasting mGluR7 receptor internalization induced by AMN082, which coincides with functional antagonism. Alternatively, AMN082's scarce selectivity for mGluR7 in vivo suggests the possibility of off-target involvement [83, 100] . AMN082 also reduces ethanol and cocaine intake [101, 102] , facilitates the extinction of aversive memories [85] , and increases colonic secretory function [26] . The recent discovery of novel negative allosteric modulators (NAMs) for mGluR7 will likely contribute to better understanding of the functional role for mGluR7 in neural functioning. 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazolo[4,5-c]pyridin-4(5H)-one (MMPIP), a selective negative allosteric modulator for mGluR7, has shown inverse agonist activity for mGluR7 and good brain exposure after systemic administration [103, 104] . In vivo studies with MMPIP have shown that negative allosteric modulation of mGluR7 impairs cognitive performance in the object recognition and radial arm maze tasks and reduces social interaction in rodents. MMPIP has been found to be ineffective in a range of behavioral experiments aimed at investigating motor coordination, anxiety and depression-like behaviors, sensorimotor gating, seizure threshold, and nociception in healthy rodents [105] . Later, a recent paper from our laboratory confirmed that, when administered into the VL PAG, MMPIP showed no effect in healthy rats but inhibited pain responses in formalin and neuropathic pain models. MMPIP altered pain thresholds by modulating the antinociceptive descending pathway at RVM levels when administered into the VL PAG. Specifically, in neuropathic rats it increased the activity of antinociceptive OFF cells and decreased that of pronociceptive ON cells, consistently with antinociception, but proved ineffective in healthy controls [106] . This context-dependent MMPIP effect was confirmed in a novel study where MMPIP was shown to reverse the main symptoms of neuropathic pain in the spared nerve injury model, while remaining ineffective in control mice. In neuropathic mice, systemic MMPIP administration increased thermal and mechanical thresholds, occurrence of open-arm choice in the elevated plus maze, reduced immobility in the tail suspension test, and reduced the number of marbles buried and digging events in the marble-burying test, thus demonstrating putative anxiolytic-and antidepressant-like properties. MMPIP also improved cognitive performance, which is deeply compromised in neuropathic mice. It appears that for mGluR7 blockade to be effective, some neuroplasticity is required. Changes in receptor expression in some supraspinal areas such as the basolateral amygdala, dorsal raphe, prelimbic cortex, PAG, and hippocampus have been observed in neuropathic conditions. This may enhance MMPIP's effect [107] . In line with the efficacy of MMPIP in chronic pain models and its lack of effect in healthy animals, MMPIP showed context-dependent activity in recombinant cell lines and inactivity under normal physiological conditions [108] . Other selective mGluR7 NAMs have recently been developed: 7-hydroxy-3-(4-iodophenoxy)-4H-chromen-4-one (XAP044), which has shown to inhibit longterm potentiation (LTP) in the lateral amygdala in brain slices from wild type mice but not in mGluR7 knockout mice, thus suggesting XAP044 specific action on mGluR7 [43] . In vivo experiments have shown that XAP044 is brain penetrant and, similar to mGluR7 knockout mice, produces anti-stress, antidepressant-, and anxiolytic-like effects and reduces freezing in a fear conditioning paradigm [43] . A single systemic XAP044 administration reverted mechanical allodynia and ameliorated anxiety-and depression-like behaviors in a model of neuropathic pain [107] . Interestingly, (+)-6-(2,4-dimethylphenyl)-2-ethyl-6,7-dihydrobenzo [d]oxazol-4(5H)-one (ADX71743), another selective mGluR7 NAM, has demonstrated excellent brain exposure after subcutaneous administration and anxiolytic-like effects in the elevated plus maze and marble burying tests. Further, ADX71743 also reduced amphetamine-induced hyperactivity without altering baseline locomotor activity [109] . The recent development of selective mGluR7 NAMs has profoundly contributed to the delineation of a functional role for mGluR7 in physiological and pathological conditions. Apart from providing a better understanding of mGluR7 function at the synapse, mGluR7 NAMs have exhibited consistent results, unlike previous ligands like AMN082. Indeed MMPIP, XAP044, and ADX71743 have demonstrated selectivity for mGluR7 and behavioral effects in line with the mGluR7-knockout phenotype. MMPIP and XAP044 have also been tested in chronic pain conditions and co-morbid affective and cognitive disorders, thus their possible therapeutic exploitation is reasonable. A summary of mGluR7 positive and negative allosteric modulators effects is presented in Table 1 .
CONCLUSIONS
The greater importance of mGluR7 of all mGluRs is unveiled by its wide distribution and its high evolutionary conservation. In particular, mGluR7 exhibits high expression in excitatory and inhibitory synapses within the brain, which are considered critical for neurologic and pathologic disorders. Being modulators of these synapses, mGluR7 ligands have a limitless potential. Initial studies using mGluR7-knockout mice have suggested that mGluR7 is involved in a series of neurological and psychiatric disorders such us epilepsy, anxiety, and depression. These effects were later confirmed by similar findings obtained using selective mGluR7 allosteric modulators. Moreover, some of the novel mGluR7 negative allosteric modulators, apart from clarifying the function of mGluR7 in fine tuning excitatory and inhibitory synapses within the CNS, have confirmed the mGluR7-knockout phenotype and clarified the role of mGluR7 in neuropsychiatric disorders. In this context, MMPIP and XAP044 have also been tested in models of neuropathic pain and have shown promising anti-allodynic, anti-anxiety-, and anti-depressant-like effects. Further, these compounds have been reported to improve cognitive performance, which is deeply affected in these models of chronic pain. As a direct consequence of these findings, further studies investigating mGluR7 negative allosteric modulator effects are expected to facilitate development of novel therapeutics for pain and pain-related affective and cognitive disorders.
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